New lease agreement in Forskaren with ITBMed

Vectura Fastigheter has signed a lease agreement in Forskaren with the Swedish-American biopharmaceutical company ITBMed. The company will establish the operation's Swedish office and lab in the building, which corresponds to an area of 500 square meters. ITBMed develops medicines in transplantation and autoimmunity. During 2022, Forskaren i Hagastaden, the new destination and meeting place for life science actors, has been filled with several new tenants.

ITBMed is a biopharmaceutical company with establishments in New York, USA and in Stockholm. The company develops immunomodulating biological drugs for use in transplantation and autoimmunity. The lead drug, spilizumab, has shown great potential to change the lives of organ transplant patients by allowing complete discontinuation of all immunosuppression therapy and return to a normal life.

ITBMed has a broad clinical study and development profile together with well-known American and European universities. Through the new establishment in Hagastaden, in Forskaren, additional conditions are provided for the continued development of ground-breaking medicines.

- Based in Forskaren, we will be able to offer an excellent meeting place to our colleagues and partners, to drive the development of our clinical studies and future drug candidates further, says Kasper Granlund, CFO at ITBMed.

During the year, Vectura, who owns and develops Forskaren, has announced several new leases in the building. Most recently ABC Labs, The Park, Villa Clinic and Urban Deli who will open a new unit with a restaurant, deli and bar on the ground floor.

- Now we see how the building is filled with activities within the life science segment. More and more people see the opportunity and advantages of establishing their businesses in Forskaren. Here, the research of the future will be conducted and new advances in life and health will become a reality. This is where ITBMed will contribute and we look forward to moving into the building, says Micael Averborg, Business Development Manager at Vectura.

Forskaren is expected to be ready for the first tenant, Elekta, to move in during the turn of the year 2023–2024 and ITBMed will move into its new premises during the summer of 2024.

ITBMed ITBMed is a biopharmaceutical development company with several ongoing clinical studies in transplantation and autoimmunity. The company has approximately 20 employees in Sweden and New York, USA. The company's main drug candidate is TCD601 (siplizumab), which is a monoclonal antibody that has shown significant potential to change the lives of organ transplant patients. www.itb-med.com.

Forskaren Forskaren in Hagastaden will bring together approximately 1,700 employees and offer 24,000 square meters of flexible offices and co-working spaces for companies with activities aimed at science and innovation for people's lives and health. On the entrance floor, other activities such as the Technical Museum, together with KI, will invite you to participate in the development of future life science through exhibitions and labs. Forskaren is expected to be completed during the fourth quarter of 2023. www.forskaren.se.